Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

21 of 40

Jonathan Allis, PET manager at GE Healthcare

Jonathan Allis, head of GE Healthcare's positron emission tomography business, sees the relationships between pharmaceuticals, diagnostics and therapeutics becoming ever closer. So the JPM experience for him amounted to this: "Talking to pharmaceutical companies from morning to night." GE has increasingly been talking to Big Pharma anyway regarding flutemetamol, the company's Alzheimer's imaging agent that regulators in the U.S. and Europe just accepted for review. But at JPM, Allis said, the conversations have become even more robust between the drug and diagnostics side of things. "We are seeing most pharmaceutical companies understanding that diagnostics are going to be much more important to them," he said.